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Peroxisomes are cellular compartments primarily associated with lipid metabolism. Most cell types,
including nervous system cells, harbor several hundred of these organelles. The importance of peroxi-
somes for central nervous systemwhite matter is evidenced by a variety of human peroxisomal disorders
with neurological impairment frequently involving the white matter. Moreover, the most frequent
childhood white matter disease, X-linked adrenoleukodystrophy, is a peroxisomal disorder. During the
past decade advances in imaging techniques have enabled the identiﬁcation of peroxisomes within the
myelin sheath, especially close to nodes of Ranvier. Although the function of myelin peroxisomes is not
solved yet on molecular level, recently acquired knowledge suggests a central role for these organelles in
axo-glial metabolism. This review focuses on the biology of myelin peroxisomes as well as on the pa-
thology of myelin and myelinated axons that is observed as a consequence of partial or complete
peroxisomal dysfunction in the brain.
 2013 The Author. Published by Elsevier Masson SAS. Open access under CC BY-NC-ND license.1. Introduction
In the nervous system axons are electrically insulated by lipid-
rich myelin sheaths that concentrically enwrap axonal segments.
These are formed by oligodendrocyte processes in the central
nervous system (CNS) and by Schwann cells in the peripheral
nervous system (PNS). Myelinated segments are interrupted by
nodes of Ranvier, a region where axonal sodium channels are
clustered to allow saltatory impulse propagation, i.e. the fast and
energy-saving conduction of action potentials between nodes [1].
In addition accumulating evidence suggests that apart from insu-
lating axons, myelin seems to serve metabolic support functions
linked to axonal energy and lipid metabolism [2e5].
Myelinated axon bundles represent the white matter tracts of
brain and spinal cord. In certain disease situations regions of CNS
white matter are demyelinated and the underlying axons often
degenerate leading to permanent neurological disability [6]. The
origin of white matter diseases can be multiple and is often directly
linked to mutations of myelin proteins, to viral infections, to an
immune system failure as in multiple sclerosis, or to metabolicMasson SAS. Open access under CC BY-Ndysfunctions [7]. One example of metabolic impairment is the
peroxisomal disorder X-linked adrenoleukodystrophy (X-ALD).
This hereditary disease is the most frequent leukodystrophy in
children. On the genetic level X-ALD is characterized by loss-of-
function mutations of the peroxisomal membrane transporter
ABCD1 [8]. Interestingly, many peroxisomal diseases are associated
with white matter abnormalities, stressing the role of peroxisomal
metabolism for the nervous system and in particular for white
matter [9].
Peroxisomes are a divers population of organelles, originally
deﬁned by the presence of catalase and oxidases in the peroxisomal
lumen [10]. Proteins involved in the biosynthesis of peroxisomes
are called peroxins (PEX) [11]. The protein content and function of
these organelles can vary between cell types and depends on the
overall metabolic demands. Hence, multiple endogenous and
exogenous factors such as cell-cycle status and environmental
conditions can inﬂuence peroxisomal turnover, constitution, and
function [12]. Peroxisomes and mitochondria perform b-oxidation
of fatty acids. However, substrate-speciﬁcity differs between the
two organelles. Exclusive substrates of peroxisomal b-oxidation
include very long chain fatty acids (VLCFA), pristanic acid, long-
chain dicarboxylic acids, certain eicosanoids and polyunsaturated
fatty acids (PUFAs) [13,14]. Also biosynthesis of plasmalogens, a
group of ether-phospholipids that is highly enriched in myelin
membranes, occurs exclusively in peroxisomes [15]. In addition a
role for peroxisomes in cholesterol biosynthesis, the major lipid
component of myelin [16], is controversially discussed [17,18].C-ND license.
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metabolism of myelinating cells, whose multi-layered membranes
consist of 70% lipids with a characteristic composition [19,20].
Furthermore, it is plausible that such high lipid content makes this
tissue especially vulnerable to a defect in lipid metabolism. How-
ever, the exact functions of peroxisomes for myelinating glia and
the axons of white matter are not well understood. It is thus
important to increase the knowledge on peroxisomal biology of
myelinating cells and its possible participation in a joined axo-glial
metabolism.
2. Peroxisomes in the nervous system
Only in the late 1960’s peroxisomes were observed in other
tissues than kidney and liver. At that time the organelles were
identiﬁed in all analyzed nucleated vertebrate cell types. It became
clear that peroxisomal morphology and cytochemistry are highly
variable between the different tissues [21]. A few years later ner-
vous system peroxisomes were analyzed for the ﬁrst time in detail
by the diaminobenzidine (DAB) cytochemical method for catalase
detection on epon-embedded electron microscopy material [22].
Notably, it was revealed that peroxisomal size in the brain is much
smaller than in other tissues, especially than in hepatocytes. This
has led to the term “microperoxisomes”.
2.1. Subcellular localization
Developmental studies showed numerous microperoxisomes in
the CNS during the ﬁrst two postnatal weeks, which were less
frequent or almost entirely absent from some regions at later stages
[23]. The increasing abundance of microperoxisomes measured by
catalase activity was observed to coincide with the onset and the
peak of myelination. Hence, Adamo and colleagues speculated on a
relationship between myelination and peroxisomes, in particular
regarding plasmalogen biosynthesis [24].
Similar to earlier studies it was conﬁrmed that the vast majority
of peroxisomes is localized in the cell soma of nervous system cells
[25]. However, peroxisomes were observed frequently in cellular
processes of astrocytes, oligodendrocytes, microglia, and Schwann
cells ([2,26] and unpublished observations). In astrocytes peroxi-
somes (200 nm in diameter) were localized in cellular processes
including the end-feet [25]. Schwann cells, the myelinating glia of
the PNS, contained numerous small peroxisomes (150 nm) [22].
Microperoxisomes were also demonstrated to reside inFig. 1. Peroxisomal localization in myelin of wild-type mice. (A) Two-photon image of cere
membrane protein 70 (PMP70, in green) with cytoplasmic myelin (CNP, in red). (B) Electron m
dots) conﬁrms a peroxisome (asterisk) within the adaxonal mesaxon.oligodendroglia, the myelinating cells of the CNS. They were also
found in the processes of oligodendrocytes adjacent to the outer
cytoplasmic mesaxon of myelin [22]. Recent immunohistochemical
work revealed the presence of multiple peroxisomes in myelinated
ﬁbers of white and gray matter, which in the majority of cases
seemed to reside within myelin, not or only rarely in axons (Fig. 1A)
[26]. Peroxisomes were abundant in all cytoplasmic regions of
myelin, i.e. the innermost (adaxonal) and outermost (abaxonal)
tongue of the sheaths, as well as specialized cytoplasmic channels
of peripheral myelin, the SchmidteLanterman incisures (Fig. 1B)
[26]. They accumulated in the vicinity of nodes of Ranvier, which
are regions of close axo-glial interaction.
In neurons the organelles were mainly detected in perikarya,
some in dendrites, but rarely within axons shown by use of the DAB
catalase staining method [22]. A recent immunohistochemical
study by Ahlemeyer and colleagues conﬁrmed this peroxisomal
localization pattern in neurons [27]. In accordance with the
observed rare localization of peroxisomes in axons, synaptic ter-
minals of the spinal cord were devoid of the organelles [22]. Syn-
apses displayed presence of peroxisomes during early development
[22], and presence of axonal peroxisomes was revealed in cultured
neurons [28,29].
The in vivo lack or low abundance of peroxisomes in CNS axons
of adult mice has been described by three independent research
groups [22,26,27]. Axonal transport of peroxisomes was demon-
strated to be blocked by tau overexpression in a primary neuronal
culture system [30]. This microtubule-associated protein is differ-
entially expressed in development [31]. Notably, the level of tau is
higher in myelinated than in unmyelinated axons [32]. However, a
possible impact of tau expression level on the in vivo transport of
axonal peroxisomes has not been studied so far.
The distribution of peroxisomes in myelinated ﬁbers leads to
speculate on a function of myelin peroxisomes for their myelinated
axons. This hypothesis has similarly been phrased already by
Holtzman and colleagues in 1973, who proposed an “involvement
of the organelles in such thing as the metabolic interrelations of
neurons and glial or satellite cells” [22].2.2. Peroxisomal diversity
Co-localization analysis concentrating on peroxisomal diversity
between different nervous system cell types was performed on
mouse brain sections and in cultured brain cells. The use of anti-
bodies recognizing peroxisomal membrane proteins and enzymesbral white matter showing the co-localization of peroxisomes stained for peroxisomal
icrograph of a callosal ﬁber after immuno-gold labeling for catalase (indicated by black
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[27]. This great heterogeneity of peroxisomal proteins possibly re-
ﬂects a differing cell type-speciﬁc spectrum of organelle functions.
In oligodendrocytes amuch higher content of catalase than in other
brain cells was detected [27]. This high peroxisomal catalase con-
tent in oligodendrocytes may account for the ﬁnding that peroxi-
somes seemed several times more abundant in oligodendrocytes
than in neurons or astrocytes when the catalase based DAB staining
method was applied [25].
Recently, it was shown that the peroxisomal protein composi-
tion found in myelin-enriched fractions differs biochemically from
the constituency of average brain peroxisomes [26]. Histological
data by Ahlemeyer and coworkers has demonstrated high expres-
sion of peroxin 14 (PEX14) in neurons and astrocytes, but less in
oligodendrocytes. Similarly, it was shown that myelin fractions
contained only minor amounts of PEX5 and PEX14, the PTS1 re-
ceptor and its corresponding docking protein [26]. Instead the
myelin fraction contained more PMP70 and was extremely
enriched in PEX11b, a peroxinmediating peroxisomal division ([26]
and unpublished observations). The prominent presence of this
peroxisomal division factor in myelin fractions suggests a high di-
vision rate for myelin peroxisomes and is consistent with the
ﬁnding of extremely small-sized myelin peroxisomes of only 50e
100 nm in diameter [26].
3. Peroxisomal dysfunction in humans e CNS and PNS
pathology
Peroxisomal disorders can be caused by mutations of peroxins
(PEX proteins). Some peroxins are essential for peroxisomal as-
sembly. Therefore loss of such an essential peroxisome biogenesis
factor leads to absence of virtually all organelle functions. These
disorders are referred to as peroxisomal biogenesis disorders (PBD)
and account for the most severe clinical phenotypes of peroxisomal
disorders belonging to the Zellweger spectrum [33]. In other cases
only a single enzymatic function or a single transporter protein of
the peroxisomal membrane are affected. According to Powers and
Moser all peroxisomal disorders with neurologic involvement may
show abnormalities of white matter in the CNS [9].
X-linked adrenoleukodystrophy (X-ALD) is a neurodegenerative
peroxisomal disorder caused bymutations of ABCD1, a peroxisomal
transporter protein [8]. ABCD1 is involved in the import of very long
chain fatty acids (VLCFA) for subsequent peroxisomal degradation
[34,35]. Consequently, VLCFA accumulate in tissues and body ﬂuids
of X-ALD patients. In the nervous system the greatest excess of
VLCFA is found in gangliosides, phosphatidylcholine, myelin-
speciﬁc proteolipid protein (PLP), and as cholesterylesters [9]. It is
a matter of extensive debate, whether or not the level of VLCFA
accumulation determines disease severity [36e38].
The neurodegenerative phenotype of X-ALD in most cases
manifests as one of twomain clinical forms: The cerebral form of X-
ALD (CALD) is characterized by white matter abnormalities. White
matter of the cerebrum and to a lesser extent of the cerebellum are
involved. Onset of demyelination is usually not before four years of
age. Approximately in two-third of the cases the lesion appears in
the parietooccipital region, progressing symmetrically towards the
frontal and temporal lobes. In one-third the lesion starts frontally
and progresses in caudal direction [38]. The spinal cord can either
remain unaffected or demonstrates bilateral white matter cortico-
spinal tract degeneration. In contrast to the cerebral demyelination,
PNS myelin of most cerebral X-ALD patients is only affected to
minor extent [9]. This is indicated by electrophysiology measure-
ments of CALD patients. Marked decrease of compound muscle
action potentials (CMAP), but only mild reductions in the nerve
conduction velocity were found (NCV) [39]. These studies suggest apredominant neuronal or axonal loss in the PNS of cerebral X-ALD
rather than demyelination. However, ultra-structural investigation
of the peripheral nerves showed a cellular pathology inmyelinating
cells, i.e. abnormal cytoplasmic inclusions in Schwann cells, but not
in neurons [40].
Adrenomyeloneuropathy (AMN) is the most common clinical
form of X-ALD with minor cerebral involvement, but degeneration
of spinal ascending and descending tracts. Particularly the cervical
fasciculus gracilis and the lumbar lateral corticospinal tracts show
comparable loss of myelin and axons [9,41]. Results of PNS elec-
trophysiology measurements obtained from AMN patients were
similar to ﬁndings of CALD patients. In the majority of 23 cases
CMAP was reduced but only mild effects on NCV were detected
[42,43].
CNS inﬂammation with massive gliosis in white matter lesions,
involvement of perivascular B cells, and invasion of CD4þ and
CD8þ T cells is a hallmark of CALD, which is absent in the neuro-
degeneration of pure AMN patients [44,45]. This has led to specu-
late on an immune-mediated pathogenesis that is responsible for
the severe demyelination in CALD, in contrast to the axonopathy
observed in AMN. When peroxisomes are impaired, myelin lipid
turnover might trigger the accumulation of lipids, e.g. inﬂamma-
tory mediators such as eicosanoids, which may actively participate
in a self-perpetuating process of demyelination [46]. However, so
far all attempts to arrest or prevent CNS demyelination in CALD
using immunosuppressive therapies have failed [47,48]. It is
necessary to establish in the future, if the invasion of lymphocytes
is helpful, harmful, or merely bystander of the disease. Interest-
ingly, bone-marrow transplantation therapy in CALD patients can
abrogate disease progression [49,50]. After transplantation healthy
donor hematopoietic stem cells can give rise to macrophages that
populate the brain in CALD [51,52]. Thus, the successful bone-
marrow therapy supports a role for microglial peroxisomes in
preventing cerebral demyelination in X-ALD. The importance of
microglia in CALD is also stressed by the observation that these cells
are lacking in the perilesional zone, which is surrounded by clusters
of activated and apoptotic microglia [53]. Compatible with these
ﬁndings chronic neuroinﬂammation with early activation of the
innate immune system has been shown inmice lacking peroxisome
function in the brain [54].
Before it was possible to assign a speciﬁc genetic defect to he-
reditary diseases, additional peroxisomal disorders were named
neonatal or pseudoneonatal adrenoleukodystrophy (NALD) ac-
cording to phenotypic similarities with X-ALD. When scientiﬁc
progress enabled the identiﬁcation of underlying genetic defects it
became apparent that mutations of several peroxisomal genes can
cause NALD: Two enzymes of the peroxisomal b-oxidation pathway
were identiﬁed, acyl-CoA oxidase (ACOX1) and HSD17B4 (also
known as multifunctional protein 2; MFP2 or D-bifunctional pro-
tein; DBP), as well as genes coding for peroxisomal biogenesis
factors (Pex1, Pex5, Pex12, and Pex6, Pex10, Pex13) [9,55]. Mutations
in one of these PEX proteins has dramatic effects on peroxisome
biogenesis leading to a generalized dysfunction of peroxisomes and
frequently to the most severe phenotype of peroxisomal disorders,
the Zellweger Syndrome (ZS). Severely impaired peroxisome
biogenesis can also result in a slightly milder clinical phenotype
with pronounced adrenal gland insufﬁciency and white matter
abnormalities, such that a close connection to the original X-ALD
disease is evident. Vice versa, inhibition of the peroxisomal b-
oxidation pathway can have similar effects and even cause a ZS-like
phenotype. It is thus tempting to speculate that impairment of
peroxisomal b-oxidation, originating from deﬁciency of either
ABCD1, ACOX1, or HSD17B4, results in loss of additional peroxi-
somal functions resembling a generalized organelle defect as in
PBD (see below).
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mutants
To investigate the pathomechanism of X-ALD, mice lacking the
homologous Abcd1 gene were generated in three independent
laboratories [56e58]. Initial analysis of these had shown the
accumulation of VLCFA, a biochemical hallmark of X-ALD, but no
signs of neurodegeneration up to the age of 12 months were
detected. In 2002 a late-onset myeloneuropathy in ABCD1-deﬁcient
mice was demonstrated. Spinal cord and peripheral nerves were
involved starting at 15 months of age [59]. Thus, these mice are a
suitable model of AMN. Further analysis of this mouse model
revealed involvement of oxidative stress and mitochondrial failure
early in the disease pathology (reviewed in Ref. [60]). While these
Abcd1-deﬁcient mice fail to show cerebral neurodegeneration,
conditional knockout mice (referred to as Cnp-Pex5 mice) lacking
peroxisomal function in myelinating cells exhibited a cerebral
phenotype. In these mice the essential peroxisomal biogenesis
factor Pex5was disrupted in a cell type-speciﬁc fashion [2]. Despite
the lack of peroxisomal function in oligodendroglia, mice displayed
normal myelination on the ultra-structural level. However, when
myelin was biochemically analyzed, highly elevated VLCFA and
severely reduced plasmalogen levels were revealed. Between three
and ﬁve months of age slight gait abnormalities became apparent.
At the same time a demyelinating lesion was illustrated by mag-
netic resonance imaging (MRI). Brain images displayed hyperin-
tense signals in the frontal subcortical white matter, the genu of
corpus callosum. The lesion progressed symmetrically in ros-
trocaudal direction (Fig. 2A) [2]. On the cellular level microgliawere
early participants, which massively invaded white matter before
obvious demyelination occurred. Perivascular B cells and T lym-
phocytes mainly of the CD8þ pool were recruited to regions un-
dergoing demyelination. This neuropathology seen in Cnp-Pex5
mice is in many aspects reminiscent of cerebral X-ALD. It isFig. 2. CNS and PNS pathology caused by dysfunction of myelin peroxisomes. (A) Magnetic r
arrows) in rostrocaudal direction. The same Cnp-Pex5 mutant mouse was monitored at 4 (l
paranodal (right) swellings in the PNS of Cnp-Pex5 mice.therefore possible that also in cerebral X-ALD especially myelin
peroxisomes acquire additional defects that trigger inﬂammatory
demyelination. Remarkably, Cnp-Pex5 animals, engineered with a
primary defect in oligodendrocytes but normal peroxisomes in
other cell types of the brain, display axonal swellings in the CNS
before demyelination can be detected. Similar observations were
made in the peripheral nervous system of these mice, where par-
anodal and axonal swellings were found without obvious de- or
dysmyelination even in aged animals (Fig. 2B [26]; and unpublished
observations). Hence, an axonal pathology can precede myelin ab-
normalities, although the original metabolic dysfunction is
restricted to myelinating cells.
The discrepancy between CNS and PNS seen in Cnp-Pex5mice is
remarkable, showing a severe central but no apparent peripheral
demyelination. This suggests that myelin peroxisomes support
myelin maintenance especially in the CNS. In contrast, support of
axonal function might be a feature of myelin peroxisomes in both,
the central and the peripheral nervous system. Further, since for-
mation of myelin in Cnp-Pex5 mice is normal, it seems that myeli-
nation can progress independent of myelin peroxisomes. However,
residual peroxisomal activity in oligodendrocytes of Cnp-Pex5mice
that is sufﬁcient for myelination cannot be ruled out. Secondly,
neighboring cells with intact peroxisomes are likely candidates to
provide peroxisomal metabolites for myelin formation. The ability
of the brain to adapt to a cell type speciﬁc dysfunction by enhancing
intercellular transfer of lipids, such as cholesterol, has been
demonstrated a few years ago [61].
Horizontal transfer of peroxisomal substrates was also sug-
gested when comparing Cnp-Pex5 mice with two additional Pex5
knockoutmutants: Micewith astroglial PEX5-deﬁciency (Gfap-Pex5
mutants) showed biochemical alterations of myelin [36,62]. CRE-
expression driven by the Nestin-promoter mediated the ablation
of peroxisomal function in neural cells. Pex5 was targeted in a
subset of neurons, in astrocytes, and in oligodendrocytes but not inesonance images of a mouse brain display the progression of hyperintense signals (red
eft), 6 (middle), and 8 (right) months. (B) Electron micrographs show axonal (left) and
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played neurodevelopmental abnormalities, developed motor im-
pairments already at 3 weeks of age, and died before 6 months.
Remarkably, in this mouse mutant the axonal pathology was
observed on other axonal segments than demyelination. In accor-
dance with ﬁndings of Cnp-Pex5 mice, the authors concluded that
peroxisomes might have a dual function in the nervous system, a
direct role for axons and one for myelin [36,63].
Additional mouse models of human peroxisomal diseases,
including neonatal adrenoleukodystrophy (NALD), have been gener-
ated. The cause of NALD is frequently a mutation in one of several
peroxins. In addition impaired peroxisomal b-oxidation bymutations
of peroxisomal enzymes ACOX1 or HSD17B4 can elicit an NALD phe-
noytpe. Astonishingly, signs of neurodegeneration were absent from
ACOX1knockoutmiceup to the age of approximately 6months,when
the animals died prematurely likely due to a liver failure [64]. Later
also the Hsd17b4 gene was ablated in mice, which caused a severe
brain pathology [36,65]. These mice displayed severe coordination
problems andmassive neuroinﬂammation,whichwas less severe but
still present in mice lacking HSD17B4 speciﬁcally in neural cells
(Nestin-Hsd17b4mice) [66]. Together, theseﬁndingsmay suggest that
peroxisomal b-oxidation is the major function of peroxisomes in the
nervous system. Alternatively, impairment of peroxisomal b-oxida-
tion may induce a secondary defect in peroxisomes, i.e. an additional
loss of peroxisomal functions. Thus, peroxisomal biogenesis disorder
phenotypes can be mirrored in mice and men when peroxisomal b-
oxidation is damaged, and vice versa.5. Axonal support by myelin peroxisomes e central players in
axo-glial metabolism?
The nature of an axonal support function that could be provided
by myelin peroxisomes remains elusive. Pieces of information areFig. 3. Hypothetical model of axonal support by myelin peroxisomes. (A) Schematic view of
ﬂanked by paranodal regions, which are deﬁned by the presence of paranodal loops (PNL). (B
by enlarged view of the axon and two paranodal loops (inset from A). Left: Neuronal N-acet
the glial compartment. Oligodendroglial aspartoacylase (ASPA) mediates the reverse reactio
that peroxisomes may take up acetate moieties derived from axonal NAA. Right: Peroxis
mitochondrial b-oxidation. Very long chain fatty acids (VLCFA) may be chain shortened
mitochondria by a carnitine dependent mechanism.available on the distribution of peroxisomes in the nervous system,
on general metabolic functions of peroxisomes, and on pathological
features seen in conditional mouse mutants. This knowledge on
peroxisomal biology prompts to speculate on possible subcellular
mechanisms that may be involved in axonal support. Myelinated
axons themselves harbor peroxisomes only rarely. However, since
peroxisomes are abundant within adaxonal myelin and accumulate
close to nodes of Ranvier, they are ideally positioned to support
axonal metabolism. Such a supportive role is likely associated with
lipid turnover and with axonal energy metabolism. In the
following, three possible functions will be illustrated.5.1. Turnover of axonal membrane constituents
Membranes contain lipid components that require peroxisomes
for degradation. Other membrane lipids are exclusively synthesized
in peroxisomes, like for example docosahexaenoic acid (C22:6),
which constitutes a major component of excitable membranes [67].
Thus, a reasonable question arises: How do axons accomplish the
turnover of exclusive peroxisomal metabolites, if peroxisomes are
absent? In this case it would be beneﬁcial for the organism to
transfer molecules between axonal compartment and myelin per-
oxisomes. Otherwise, movement of peroxisomal metabolites would
require energy dependent retrograde and anterograde transport
between synapses and neuronal perikarya, where neuronal per-
oxisomes are located. Considering the lengths of axons, the
shortcut between axons and myelin peroxisomes would likely be
an energy saving solution to the problem.
Experiments showing the localization of axon-derived mole-
cules in Schwann cells have been performed several years ago [68].
After injecting ﬂuorescent tracers, axonal transport and seques-
tration thereof by Schwann cells were observed. Uptake occurred
speciﬁcally in paranodal areas, far away from the injection sites. Atwo adjacent myelinated axonal segments, separated by a node of Ranvier. The node is
) Two possible axonal support functions of myelin peroxisomes (orange) are illustrated
yltransferase 8-like (NAT8L) produces N-acetylaspartate (NAA), which is transferred to
n producing acetate and -aspartate. It is hypothesized (indicated by a question mark)
omal b-oxidation might modify fatty acids thereby producing suitable substrates for
by peroxisomal metabolism. The resulting fatty acids may be transported to axonal
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responsible for the exchange of peroxisomal metabolites between
myelin and axons. In addition, such a shuttling mechanism be-
tween axons and myelin would also be consistent with the accu-
mulation of vesicles in the paranodal region of Cnp-Pex5 mutants
and in other dying-back axonopathies, as suggested earlier [26,69].
The intriguing question remains about possible advantages of such
a complex shuttling mechanism over axons possessing own
peroxisomes.
5.2. Synthesis of myelin lipids
Althoughmyelinwith reduced plasmalogen and elevated VLCFA
levels can initially be formed in the CNS of mutants lacking myelin
peroxisomes, myelin cannot be maintained in brains of adult mice
[2]. Hence, an important issue is to clarify whether peroxisomes
could contribute to myelin turnover by additional, yet unknown
lipid synthesis pathways. Several years ago, experiments with 14C-
labeled N-acetylaspartate (NAA) suggested the incorporation of
acetate derived from neuronal NAA into myelin lipids [70]. NAA is a
major amino acid derivate of the mammalian brain. This molecule
is generated by the neuronal enzyme N-acetyltransferase 8-like
(NAT8L) and delivered to oligodendrocytes. Aspartoacylase
(ASPA), which is an exclusive oligodendroglial enzyme, degrades
NAA into its acetate and aspartate moieties [71]. A peroxisome
dependent acetate metabolism for lipid synthesis has been
considered earlier as a result of experiments in plants [72]. Also,
other experiments in fungi supported a peroxisomal function in
acetate metabolism [73]. Remarkably, if comatose, the Arabidopsis
homolog of the Abcd1 gene is lacking, the seedlings’ acetate
metabolism is compromised [74]. This obliges to ask, whether
mammalian ABCD1 could have a function in acetate metabolism as
well (Fig. 3B, left).
5.3. Support of axonal energy metabolism
Absence of functional peroxisomes from myelin forming glia
leads to APPþ swellings [2,26], a pathology that is interpreted as
lack of energy for axonal transport [75]. Peroxisomes are capable of
performing b-oxidation of fatty acids that is probably involved in
cellular energy production, e.g. by mobilization of storage lipids
[76e78]. Hence, myelin peroxisomes might support axons by de-
livery of energy-rich metabolites. Fatty acids with chain lengths
that are suitable for mitochondrial b-oxidation could be interesting
candidates. Such fatty acids could for example derive from perox-
isomal b-oxidation of VLCFA that require chain shortening to be
accepted as substrates by mitochondrial b-oxidation. Subsequent
binding to L-carnitine could possibly enable the transport from
myelin peroxisomes to axonal mitochondria through high afﬁnity
carnitine-transporters. These transporters seem to be present in all
membranes that have to be passed to allow such a transport route
[79e81]. The observed accumulation of neuronal L-carnitine, which
cannot be explained so far, would be consistent with this hypoth-
esis [82]. In addition, a cluster of genes that is tied to lipid energy
metabolism is highly expressed in the adult mouse sciatic nerves
[83]. It is thus tempting to imagine myelin lipids as an energy
storage reservoir for the brain that can be mobilized by myelin
peroxisomes (Fig. 3B, right).
6. Conclusions
Shortly after peroxisomes were observed in the nervous system
by electron microscopy, it was speculated that they play an
important role in white matter. This conclusion is supported by the
identiﬁcation of human peroxisomal disorders that are frequentlyassociated with white matter abnormalities. Furthermore, genetic
manipulation and analysis of mutant mice have conﬁrmed the
importance of peroxisomes for myelin maintenance and for the
integrity of myelinated axons: Analysis of Cnp-Pex5 mice has
demonstrated that myelin peroxisomes seem to serve a direct
axonal support function, in both CNS and PNS. In contrast, myelin
peroxisomes are important for myelin maintenance primarily in
the CNS, which exhibits severe demyelination, while PNS myelin is
spared when myelin peroxisomes are impaired. On the molecular
level peroxisomal functions that are required to prevent neuro-
degeneration remain elusive. Therefore, one major future task is to
better characterize the cell type speciﬁc heterogeneity of the
peroxisomal populations in the nervous system.
The term “adrenoleukodystrophy” encompasses a heteroge-
neous group of peroxisomal disorders. ALD might originate from a
defect in peroxisomal biogenesis that affects all peroxisomal
functions. Alternatively, ALD can be caused by defects in a single
protein (i.e. ABCD1, ACOX1, or HSD17B4) leading to impairment of
peroxisomal b-oxidation. Thus, interfering with peroxisomal b-
oxidation can lead to clinical symptoms that phenocopy the com-
plete loss of peroxisomal functions, and vice versa. This is further
illustrated by the CALD-like phenotype in mice with complete loss
of peroxisomal function in myelinating glia.
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